Chiroscience Group Plc was a British-based biotech company, founded by Christopher Evans. The company was taken over by Celltech in 1999, which was acquired in 2004 by UCB.
History Chiroscience was born from the demise of the company Enzymatix, which was ultimately acquired by Genzyme, when Andrew Richards joined the company and convinced Evans and Peter Keen to launch Chiros, name of which was quickly revised to Chrioscience. Seed funding for the company of £3 million was provided by Schroder Ventures, Apax and 3i. Chiroscience became one of the first biotechnology Initial Public Offerings in the United Kingdom in 1994. In 1996, the company merged with the American biotech company Darwin Molecular Corporation, based in Cambridge, Massachusetts, retaining Chiroscience as its name. By the time of its merger with Celltech in 1999, both Chris Evans and Peter Keen had left the company, leaving Andrew Richards as the sole remaining founder and original board member.
See also Chirocaine, an anesthetic developed by Chiroscience Romosozumab, discovered by Chiroscience before its acquisition by Celltech Pharmaceutical industry in the United Kingdom
References and notes
Further reading Datastream (May 8, 1996). "Chiroscience on the up". The Guardian. London, England. p. 21. Retrieved December 24, 2018 – via Newspapers.com. This shows performance of stock from May 1995 to May 1996. Murphy, Paul (April 26, 1996). "Market report". The Guardian. London, England. p. 20. Retrieved December 24, 2018 – via Newspapers.com. On Mr. Buffet's terms, Chiroscience is nothing more than a bag of dreams. Contains a graphic showing company stock performance across 1994 to 1996.
External links UCB Group website Archived October 4, 2006, at the Wayback Machine